Scholar Rock (NASDAQ:SRRK) Sees Unusually-High Trading Volume on Strong Earnings

Scholar Rock Holding Corporation (NASDAQ:SRRK) saw an uptick in trading volume on Wednesday following a stronger than expected earnings report. 2,499,630 shares changed hands during mid-day trading, an increase of 148% from the previous session’s volume of 1,008,784 shares.The stock last traded at $44.10 and had previously closed at $44.31.

The company reported ($0.76) EPS for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.10. During the same quarter in the previous year, the company earned ($0.64) EPS.

Key Stories Impacting Scholar Rock

Here are the key news stories impacting Scholar Rock this week:

• Positive Sentiment: BMO Capital Markets raised its price target from $50 to $70 and kept an “outperform” rating (~47.6% upside vs. the current price). BMO Raises PT to $70
• Positive Sentiment: Citigroup raised its target to $58 and maintained a “buy” rating (~22% upside). Citigroup Raises PT to $58
• Positive Sentiment: Piper Sandler raised its target to $58 and kept an “overweight” rating (similar ~22% upside). Piper Sandler PT Raise Street Insider
• Positive Sentiment: HC Wainwright reaffirmed a “buy” and a $58 target. HC Wainwright Reaffirmation TickerReport
• Positive Sentiment: Q4 results narrowly beat expectations — reported EPS (net loss) was ($0.76) vs. consensus (~$0.86), which analysts viewed positively relative to estimates. Earnings Release / Summary
• Neutral Sentiment: Full earnings and Q&A transcripts are now available (multiple outlets posted call transcripts), useful for digging into pipeline updates and management tone. Seeking Alpha Transcript InsiderMonkey Transcript
• Negative Sentiment: Despite the beat, the corrected press release clarifies net loss per share was $0.76 for Q4 vs. $0.61 a year earlier — an increase in the loss year‑over‑year, underscoring ongoing unprofitability. BusinessWire Correction

Analyst Ratings Changes

A number of equities research analysts have commented on the company. HC Wainwright restated a “buy” rating and issued a $58.00 target price on shares of Scholar Rock in a research report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Scholar Rock in a report on Thursday, January 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Scholar Rock in a research report on Thursday, December 11th. Piper Sandler upped their price target on Scholar Rock from $51.00 to $58.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, Wolfe Research started coverage on Scholar Rock in a report on Tuesday, November 18th. They set an “outperform” rating and a $42.00 price objective on the stock. Four investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $54.14.

Insider Buying and Selling at Scholar Rock

In other Scholar Rock news, COO Keith Woods sold 16,746 shares of the firm’s stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $42.70, for a total value of $715,054.20. Following the completion of the sale, the chief operating officer owned 583,254 shares of the company’s stock, valued at approximately $24,904,945.80. This trade represents a 2.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Vikas Sinha sold 16,755 shares of the firm’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $42.70, for a total transaction of $715,438.50. Following the sale, the chief financial officer directly owned 583,245 shares in the company, valued at $24,904,561.50. This represents a 2.79% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 208,470 shares of company stock worth $9,201,778. 13.30% of the stock is currently owned by company insiders.

Institutional Trading of Scholar Rock

Institutional investors and hedge funds have recently bought and sold shares of the company. AQR Capital Management LLC raised its position in shares of Scholar Rock by 609.3% during the 1st quarter. AQR Capital Management LLC now owns 57,294 shares of the company’s stock worth $1,842,000 after purchasing an additional 49,217 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Scholar Rock by 12.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,046 shares of the company’s stock valued at $1,709,000 after buying an additional 5,831 shares during the period. Millennium Management LLC lifted its holdings in shares of Scholar Rock by 37.4% during the 1st quarter. Millennium Management LLC now owns 200,255 shares of the company’s stock valued at $6,438,000 after buying an additional 54,555 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Scholar Rock by 25.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 169,825 shares of the company’s stock valued at $5,460,000 after purchasing an additional 34,594 shares in the last quarter. Finally, Strs Ohio acquired a new stake in shares of Scholar Rock in the first quarter worth $77,000. Institutional investors and hedge funds own 91.08% of the company’s stock.

Scholar Rock Price Performance

The company has a debt-to-equity ratio of 0.41, a current ratio of 6.30 and a quick ratio of 6.30. The company has a market capitalization of $4.84 billion, a P/E ratio of -13.83 and a beta of 0.70. The stock’s fifty day simple moving average is $45.32 and its 200-day simple moving average is $39.14.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).